On September 28, 2022 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, reported Ripal Gandhi, M.D., FSIR, FSVM presented, "Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer," at the recent Symposium on Clinical Interventional Oncology (CIO) (Press release, Renovorx, SEP 28, 2022, View Source [SID1234621522]). Dr. Gandhi is a course director for the symposium recently held September 23-25, 2022 at the Loews Hotel in Miami Beach, Florida. View Dr. Gandhi’s full presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Gandhi is a professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine. Since 2018, Dr. Gandhi has been instrumental in the multi-center Phase 3 TIGeR-PaC clinical trial as a principal investigator for the Miami Cancer Institute.
Dr. Gandhi’s presentation, "Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer," provides an overview of the clinical challenges of the standard-of-care treatment, available to locally advanced pancreatic cancer (LAPC) patients. Systemic (intravenous) chemotherapy is considered the standard of care for LAPC and is often associated with debilitating side effects. It may be ineffective in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy.
Dr. Gandhi highlighted the RenovoTAMP therapy platform’s potential as a targeted oncology option for LAPC patients. The presentation showcased RenovoRx’s RR1 Phase I/II and RR2 Observational Registry studies suggesting when RenovoTAMP is used in combination with radiation therapy, arterial microvasculature may be reduced, minimizing chemotherapy leakage during delivery. Increasing chemotherapy directly to the tumor could reduce systemic side effects. Dr. Gandhi also presented about the mission and protocol behind the TIGeR-PaC study.
The TIGeR-PaC study is evaluating RenovoRx’s first product candidate, RenovoGem, to treat LAPC through RenovoTAMP’s intra-arterial delivery of gemcitabine, an FDA-approved chemotherapy. Study goals include extension of patient survival, reduction of side-effects associated with systemic chemotherapy, and improved quality of life for pancreatic cancer patients.
"The CIO symposium aims to educate on the most viable and sought-after treatments in the rapidly growing practice of interventional oncology management," said Ramtin Agah, M.D., Chief Medical Officer and Founder of RenovoRx. "As a recognized expert in this field, we appreciate Dr. Gandhi highlighting our therapy platform as a potential option for difficult-to-treat cancers, like LAPC."
"Over the past decade, our team has refined RenovoTAMP. Results of Phase 1/2 and observational registry studies suggest RenovoTAMP may enhance patient survival while countering chemotherapy tolerability issues. The result could be improved quality of life for patients and their loved ones. Our team continues making progress enrolling the TIGeR-PaC study. We look forward to reporting the first prospective interim analysis for the study, which is expected in the fourth quarter of this year."